PGs5 Inhibitors
Chemical inhibitors of PGs5 can modulate the activity of this protein by interacting with specific signaling pathways that are crucial for its function. MK-2206, an allosteric inhibitor of AKT, can reduce the phosphorylation and activation of downstream targets, which includes PGs5 if it is a substrate or regulated by the AKT pathway. Similarly, LY294002 and Wortmannin, both of which are inhibitors of PI3K, can decrease AKT activity leading to a downregulation of PGs5 function if it falls under the PI3K/AKT signaling umbrella. Triciribine and GSK690693, by specifically targeting AKT phosphorylation and activation, can also inhibit the activity of PGs5 by impeding the signaling processes that contribute to its regulation. Perifosine, which impedes AKT activation at the plasma membrane, and AZD5363, which binds to AKT's ATP-binding pocket, can likewise suppress the PGs5 protein's activity through their influence on the AKT signaling pathway.
U0126, PD98059, and SL327 are inhibitors that target the MAPK/ERK pathway by inhibiting MEK1/2, which could lead to the inhibition of PGs5 if it is a downstream effector of this pathway. The disruption of MEK1/2 activation prevents the phosphorylation of ERK, which can subsequently inhibit the function of PGs5 if it is regulated by the MAPK/ERK signaling cascade. Sorafenib, which targets multiple kinases, including those in the RAF family and various receptor tyrosine kinases (RTKs) that are part of the MAPK/ERK pathway, can also inhibit the function of PGs5. By obstructing these kinases, Sorafenib can disrupt the downstream signaling that potentially governs the activity of PGs5. These chemical inhibitors, by targeting key nodes within these signaling networks, can effectively modulate the function of PGs5 depending on its placement and role within these pathways.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an allosteric inhibitor of AKT, a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration. Inhibition of AKT by MK-2206 can reduce the phosphorylation and activation of downstream targets, which may include PGs5 if PGs5 is a substrate of AKT or is regulated by the AKT signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the AKT signaling pathway. By inhibiting PI3K, LY294002 can decrease AKT activity and subsequent phosphorylation of downstream targets, potentially including PGs5, thereby inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of the mTOR (mammalian target of rapamycin) pathway, which is also upstream of the AKT signaling pathway. Inhibition of mTOR can lead to reduced AKT activity and affect its downstream effectors, potentially inhibiting PGs5 if it is part of this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, similar to LY294002. By inhibiting PI3K activity, wortmannin can decrease AKT signaling and downregulate the phosphorylation of downstream proteins, which could include PGs5 if it is involved in the PI3K/AKT pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits AKT phosphorylation and activation, without affecting other kinases. By inhibiting AKT, triciribine impacts the AKT signaling pathway and its downstream targets, which could lead to inhibition of PGs5 if it is regulated by this pathway. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an ATP-competitive inhibitor of AKT. This inhibition can decrease the phosphorylation of AKT substrates, potentially leading to the inhibition of PGs5 function if this protein is a downstream target in the AKT pathway. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that inhibits AKT activation in the plasma membrane. By inhibiting the AKT pathway, perifosine could decrease the activity of downstream proteins including PGs5, assuming PGs5 is a part of or regulated by this pathway. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is an inhibitor of AKT that binds to the ATP-binding pocket of the enzyme. Inhibition of AKT by AZD5363 would lead to reduced activity of downstream signaling components, which could lead to the functional inhibition of PGs5 if it is influenced by AKT. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key kinases in the MAPK/ERK pathway. Inhibition of the MAPK/ERK pathway can alter cellular functions regulated by this pathway, which may include the inhibition of PGs5 if PGs5 is a downstream effector in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that functions similarly to U0126. It blocks MEK1/2 activation in the MAPK/ERK pathway, potentially inhibiting downstream targets such as PGs5 if PGs5's activity is influenced by the MAPK/ERK pathway. | ||||||